

Sino Biopharmaceutical Limited

Equitable Pricing Policy

1. Purpose

Sino Biopharmaceutical Limited together with its subsidiaries (hereinafter referred to as "Sino Biopharmaceutical", "the Group") adheres to the mission of "Science for a healthier world" and is committed to providing patients and customers with high-quality, fair and accessible products and services. In order to further share the development results of the pharmaceutical and health industry with all relevant parties and adhere to the principle of "equitable pricing", the policy is formulated.

2. Applicability

Unless otherwise specified, the policy applies to all products of the Group.

3. Principle of Fair Pricing

Legal compliance: The Group's pricing strategy shall comply with the laws, regulations, and other regulatory requirements of each location of operation and not harm public interests and other citizens' legitimate rights and interests.

Fairness and openness: The Group's pricing strategy should align with the principle of fairness and disclose the prices of its products.

Accessibility. The Group's pricing strategy needs to be based on actual cost inputs, clinical value and patient affordability to set and adjust prices reasonably and continue to improve accessibility of medicines.

4. Equitable Pricing Initiatives

Sino Biopharmaceutical's product pricing is in strict compliance with the laws, regulations and other regulatory requirements of the locations in which it operates, and it adheres to pricing compliance to protect the legitimate rights and interests of patients.

Sino Biopharmaceutical strictly follows the principle of fair and open pricing, and discloses the sales prices of various types of drugs on the centralized drug procurement platforms in each province, and for the varieties that win the national centralized drug procurement, the winning prices are also disclosed on the Joint Tendering Network (JTN).

Sino Biopharmaceutical is committed to enhancing the accessibility of medicines. At the pricing level, the Group adopts a value-based pricing approach, whereby the pricing of pharmaceutical products is based on cost inputs and their overall value to patients, the healthcare system and the local community, in order to incentivize the Group to continue to deepen its investment in the field of drug development. In order to benefit more patients with its products, the Group actively participates in healthcare insurance negotiations in the mainland China market to increase the coverage of its drugs in healthcare institutions and to benefit people's livelihood with better pricing. In Hong Kong, Macao, Taiwan and overseas markets, the Group adopts a differentiated pricing

approach, taking into full consideration factors such as the level of economic development, healthcare system policies and patients' ability to pay in each country and region, and the pricing of medicines in the same level of country, region or market is relatively consistent; at the same time, the Group also formulates more accessible pricing strategies based on the needs and ability to pay of patients in different countries/regions in order to serve more patients globally. We will also develop more accessible pricing strategies based on the needs and affordability of patients in different countries/regions to serve more patients worldwide.

5. Implementation and Supervision

The Board of Directors is responsible for setting the strategy and objectives for medical accessibility, including fair pricing, and the Chairman of the Board of Directors is the Board-level representative under this topic. The Group Management, with the Group Strategic Decision-making Committee taking over from the Board of Directors, is responsible for the specific work of medical accessibility management. The member companies support the implementation of the relevant work under the leadership and supervision of the Group.

6. Supplementary Provisions

Anything not covered in this policy, or contrary to the relevant laws, regulations, or normative documents of the People's Republic of China, should be implemented in accordance with the relevant laws, regulations, or normative documents of the People's Republic of China.